08/28/2026
**Another remarkable frontier for proton therapy — this time, the heart.**
For decades, proton therapy has been best known for its precision in treating cancer. Now, research from **Mayo Clinic** demonstrates how that same technology may have applications well beyond oncology.
In a first-in-human early feasibility study, Mayo Clinic researchers used **noninvasive proton beam therapy to treat refractory ventricular tachycardia (VT)** — a potentially life-threatening heart rhythm disorder in patients who had already undergone other treatments.
The early results are impressive: **VT burden was reduced by approximately 79%**, with treatment delivered in a single noninvasive session and without anesthesia.
What makes this especially fascinating is one of proton therapy’s fundamental advantages: its ability to precisely target abnormal tissue while limiting radiation exposure to surrounding healthy tissue.
And could this eventually have implications for other heart rhythm disorders?
While this Mayo study focused specifically on ventricular tachycardia — **not atrial fibrillation (AFib)** — earlier research has examined the feasibility of proton-based approaches to pulmonary vein isolation, a major target in AFib ablation. It raises an intriguing question about where **noninvasive proton cardiac ablation** could ultimately lead.
Much more research and longer-term follow-up will be necessary. But seeing proton technology move from treating tumors to potentially treating abnormal electrical pathways within a beating heart is an extraordinary development.
**The continuing evolution of proton therapy is remarkable to watch.**
Congratulations to the multidisciplinary teams at Mayo Clinic advancing this important research.
Read the Mayo Clinic report:
https://www.mayoclinic.org/medical-professionals/cardiovascular-diseases/news/first-in-human-noninvasive-proton-beam-therapy-for-treating-ventricular-tachycardia/mac-20607725
